Cancer Registry Software Market Size, Share, Opportunities, And Trends By Type (Integrated Software, Standalone Software), By Deployment Mode (On-premise, Cloud-based), By Database (Commercial Database, Public Database), By Functionality (Cancer Reporting, Patient Care Management, Product Outcome Evaluation, Medical Research And Clinical Studies), By End User (Government Organizations & Third-party Administrators, Hospitals & Medical Practices, Pharmaceutical, Biotechnology, & Medical Device Companies, Private Payers, Research Centers), And By Geography - Forecasts From 2024 To 2029
- Published : Feb 2024
- Report Code : KSI061616697
- Pages : 147
Offered with this report
Market Data and Estimates in Excel
2 Months of Post Sale Analyst Support
Requirement Specific Customization
The cancer registry software market is witnessing significant growth driven by the increasing burden of cancer worldwide and the need for robust data management solutions. Cancer registry software plays a pivotal role in collecting, storing, and analyzing data related to cancer cases, treatments, and outcomes. These software solutions provide healthcare institutions, research organizations, and government agencies with valuable insights into cancer trends, patient demographics, and the effectiveness of treatment protocols.
With advancements in technology, including the integration of artificial intelligence and machine learning capabilities, cancer registry software offers enhanced functionality and accuracy in data analysis. Moreover, the growing emphasis on population health management and evidence-based decision-making further propels the demand for cancer registry software. As cancer continues to pose a significant global health challenge, the cancer registry software market is expected to continue its upward trajectory in the coming years, supporting efforts to improve cancer prevention, diagnosis, and treatment outcomes.
Market Drivers
- Rising rate of cancer cases
According to projections from the International Agency for Research on Cancer (IARC) as of July 2021, it is anticipated that by 2040, the worldwide incidence of cancer will rise to 27.5 million new cases, with 16.3 million deaths attributed to the disease. This substantial increase in cancer prevalence underscores the growing need for cancer registry software, which offers valuable insights into cancer trends and treatment approaches.
- Operational disruptions
- In January 2022, a research study titled "Impact of the COVID-19 Pandemic on Population-based Cancer Registry" revealed that numerous cancer registries experienced operational disruptions in the initial stages of the pandemic. To safeguard the sustainability of cancer surveillance globally, governments must demonstrate ongoing support for registry operations as a crucial tool in disease management. Transitioning towards electronic reporting systems is also advocated to enhance efficiency and resilience in cancer surveillance efforts.
North America is anticipated to hold a significant share of the market
The North American region is projected to lead the market, driven by the rising prevalence of chronic conditions such as cancer and the introduction of new products. As per the Cancer Statistics 2021 report by the American Cancer Society Journal, approximately 1.9 million new cancer cases and 608,570 cancer-related deaths were recorded in the United States, significantly influencing market growth. Additionally, data from Globocan 2020 indicates that the country had 274,364 new cancer cases in 2020, with projections suggesting an increase to 400,564 by 2040. Therefore, the escalating burden of cancer cases in the country is anticipated to propel market expansion.
Market Developments
- In May 2022, Kaiku Health and Roche announced a collaborative partnership focused on digital patient monitoring and management (DPMM). The objective of this partnership is to leverage digital tools to enhance real-time symptom management for both patients and healthcare providers (HCPs), enhance patient support services, and deliver personalized cancer care to cancer clinics and patients worldwide.
- In March 2022, Elekta announced that the National Health Service Supply Chain (NHSSC) had procured several licenses for Elekta's ProKnow software solution. This software centralizes and analyzes radiotherapy data within a secure and scalable platform, making it accessible to radiation oncology facilities across NHS England (NHSE).
- In August 2021, the International Agency for Research on Cancer (IARC) collaborated with The Northern Ireland Cancer Registry to develop new software aimed at enhancing cancer staging. The goal is to bolster national cancer control efforts through the improved collection of standardized and comparable data.
Market Segmentation
- By Type
- Integrated Software
- Standalone Software
- By Deployment mode
- On-premise
- Cloud-based
- By Database
- Commercial database
- Public database
- By Functionality
- Cancer Reporting
- Patient Care Management
- Product Outcome Evaluation
- Medical Research and Clinical Studies
- By End User
- Government Organizations & Third-party Administrators
- Hospitals & Medical Practices
- Pharmaceutical, Biotechnology, & Medical Device Companies
- Private Payers
- Research Centers
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Others
- Asia Pacific
- Japan
- China
- India
- South Korea
- Taiwan
- Thailand
- Indonesia
- Others
- North America
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
1.8. Key Benefits to the stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. CANCER REGISTRY SOFTWARE MARKET BY TYPE
5.1. Introduction
5.2. Integrated Software
5.2.1. Market Opportunities and Trends
5.2.2. Growth Prospects
5.3. Standalone Software
5.3.1. Market Opportunities and Trends
5.3.2. Growth Prospects
6. CANCER REGISTRY SOFTWARE MARKET BY DEPLOYMENT MODE
6.1. Introduction
6.2. On-Premise
6.2.1. Market Opportunities and Trends
6.2.2. Growth Prospects
6.3. Cloud Based
6.3.1. Market Opportunities and Trends
6.3.2. Growth Prospects
7. CANCER REGISTRY SOFTWARE MARKET BY DATABASE
7.1. Introduction
7.2. Commercial Databases
7.2.1. Market Opportunities and Trends
7.2.2. Growth Prospects
7.3. Public Databases
7.3.1. Market Opportunities and Trends
7.3.2. Growth Prospects
8. CANCER REGISTRY SOFTWARE MARKET BY FUNCTIONALITY
8.1. Introduction
8.2. Cancer Reporting
8.2.1. Market Opportunities and Trends
8.2.2. Growth Prospects
8.3. Patient Care Management
8.3.1. Market Opportunities and Trends
8.3.2. Growth Prospects
8.4. Product Outcome Evaluation
8.4.1. Market Opportunities and Trends
8.4.2. Growth Prospects
8.5. Medical Research and Clinical Studies
8.5.1. Market Opportunities and Trends
8.5.2. Growth Prospects
9. CANCER REGISTRY SOFTWARE MARKET BY END-USER
9.1. Introduction
9.2. Government Organizations & Third-party Administrators
9.2.1. Market Opportunities and Trends
9.2.2. Growth Prospects
9.3. Hospitals & Medical Practices
9.3.1. Market Opportunities and Trends
9.3.2. Growth Prospects
9.4. Pharmaceutical, Biotechnology, & Medical Device Companies
9.4.1. Market Opportunities and Trends
9.4.2. Growth Prospects
9.5. Private Payers
9.5.1. Market Opportunities and Trends
9.5.2. Growth Prospects
9.6. Research Centers
9.6.1. Market Opportunities and Trends
9.6.2. Growth Prospects
10. CANCER REGISTRY SOFTWARE MARKET BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. By Type
10.2.2. By Deployment Mode
10.2.3. By Database
10.2.4. By Functionality
10.2.5. By End-User
10.2.6. By Country
10.2.6.1. United States
10.2.6.1.1. Market Opportunities and Trends
10.2.6.1.2. Growth Prospects
10.2.6.2. Canada
10.2.6.2.1. Market Opportunities and Trends
10.2.6.2.2. Growth Prospects
10.2.6.3. Mexico
10.2.6.3.1. Market Opportunities and Trends
10.2.6.3.2. Growth Prospects
10.3. South America
10.3.1. By Type
10.3.2. By Deployment Mode
10.3.3. By Database
10.3.4. By Functionality
10.3.5. By End-User
10.3.6. By Country
10.3.6.1. Brazil
10.3.6.1.1. Market Opportunities and Trends
10.3.6.1.2. Growth Prospects
10.3.6.2. Argentina
10.3.6.2.1. Market Opportunities and Trends
10.3.6.2.2. Growth Prospects
10.3.6.3. Others
10.3.6.3.1. Market Opportunities and Trends
10.3.6.3.2. Growth Prospects
10.4. Europe
10.4.1. By Type
10.4.2. By Deployment Mode
10.4.3. By Database
10.4.4. By Functionality
10.4.5. By End-User
10.4.6. By Country
10.4.6.1. United Kingdom
10.4.6.1.1. Market Opportunities and Trends
10.4.6.1.2. Growth Prospects
10.4.6.2. Germany
10.4.6.2.1. Market Opportunities and Trends
10.4.6.2.2. Growth Prospects
10.4.6.3. France
10.4.6.3.1. Market Opportunities and Trends
10.4.6.3.2. Growth Prospects
10.4.6.4. Italy
10.4.6.4.1. Market Opportunities and Trends
10.4.6.4.2. Growth Prospects
10.4.6.5. Spain
10.4.6.5.1. Market Opportunities and Trends
10.4.6.5.2. Growth Prospects
10.4.6.6. Others
10.4.6.6.1. Market Opportunities and Trends
10.4.6.6.2. Growth Prospects
10.5. Middle East and Africa
10.5.1. By Type
10.5.2. By Deployment Mode
10.5.3. By Database
10.5.4. By Functionality
10.5.5. By End-User
10.5.6. By Country
10.5.6.1. Saudi Arabia
10.5.6.1.1. Market Opportunities and Trends
10.5.6.1.2. Growth Prospects
10.5.6.2. UAE
10.5.6.2.1. Market Opportunities and Trends
10.5.6.2.2. Growth Prospects
10.5.6.3. Others
10.5.6.3.1. Market Opportunities and Trends
10.5.6.3.2. Growth Prospects
10.6. Asia Pacific
10.6.1. By Type
10.6.2. By Deployment Mode
10.6.3. By Database
10.6.4. By Functionality
10.6.5. By End-User
10.6.6. By Country
10.6.6.1. Japan
10.6.6.1.1. Market Opportunities and Trends
10.6.6.1.2. Growth Prospects
10.6.6.2. China
10.6.6.2.1. Market Opportunities and Trends
10.6.6.2.2. Growth Prospects
10.6.6.3. India
10.6.6.3.1. Market Opportunities and Trends
10.6.6.3.2. Growth Prospects
10.6.6.4. South Korea
10.6.6.4.1. Market Opportunities and Trends
10.6.6.4.2. Growth Prospects
10.6.6.5. Taiwan
10.6.6.5.1. Market Opportunities and Trends
10.6.6.5.2. Growth Prospects
10.6.6.6. Thailand
10.6.6.6.1. Market Opportunities and Trends
10.6.6.6.2. Growth Prospects
10.6.6.7. Indonesia
10.6.6.7.1. Market Opportunities and Trends
10.6.6.7.2. Growth Prospects
10.6.6.8. Others
10.6.6.8.1. Market Opportunities and Trends
10.6.6.8.2. Growth Prospects
11. COMPETITIVE ENVIRONMENT AND ANALYSIS
11.1. Major Players and Strategy Analysis
11.2. Market Share Analysis
11.3. Mergers, Acquisitions, Agreements, and Collaborations
11.4. Competitive Dashboard
12. COMPANY PROFILES
12.1. C/NET Solutions
12.2. Conduent Inc.
12.3. Electronic Registry System Inc.
12.4. Elekta
12.5. McKesson Corporation
12.6. NeuralFrame, Inc.
12.7. Onco Inc.
12.8. Ordinal Data Inc.
12.9. Epic Systems
C/NET Solutions
Conduent Inc.
Electronic Registry System Inc.
Elekta
McKesson Corporation
Onco Inc.
Ordinal Data Inc.
Epic Systems
Related Reports
| Report Name | Published Month | Get Sample PDF |
|---|---|---|
| Global Cancer Immunotherapy Market Size & Share | 2019 - 2024 | Mar 2023 | |
| Cancer Diagnostics Market Size & Share: Industry Report, 2023-2028 | Sep 2023 | |
| Cancer Gene Therapy Market Size: Industry Report, 2023 – 2028 | Oct 2023 | |
| Colorectal Cancer Screening Market Trends: Report, 2023-2028 | Dec 2023 | |
| Cancer Cachexia Market Size, Share & Trends: Report, 2024-2029 | Feb 2024 |